On October 29, the Prostate Cancer Session will include a State of the Art Lecture from Leonard Marks, MD, from UCLA. Dr. Marks is a professor of urology at the David Geffen School of Medicine at UCLA. He was founder and medical director of Urological Sciences Research Foundation, a California non-profit organization (501c3), from its inception in 1992 through year-end 2008, when he joined the UCLA Department of Urology full-time. During that 17 year period, he led numerous studies on prostate diseases and men’s health and accumulated a publication list totaling more than 100 peer-reviewed articles.
Dr. Marks will speak on the Evolution of Targeted Prostate Biopsy at the Maui meeting.
The first will be from Christopher Amling, MD, of Oregon Health & Science University (OSHU). Dr. Amling is head of Division of Urology in the OHSU Department of Surgery. He is a national and international authority on the latest prostate cancer treatments, including surgery with the da Vinci robotic system. He has also developed new ways to educate surgical residents and published many articles in medical journals on diagnosing and treating prostate cancer. He is board certified in urology and is a fellow of the American College of Surgeons and a member of the American Urologic Association.
Dr. Amgling’s presentation is titled Imaging of the Prostate: From Diagnosis and Staging to Treatment Selection.
Dr. Amling’s presentation will be followed by a presentation from Matthew Cooperberg, MD. Dr. Cooperberg is a genitourinary cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center. He specializes in the diagnosis and management of genitourinary cancer, and using minimally invasive techniques to treat benign and malignant diseases. He developed a new prostate cancer risk assessment tool called the Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score.
Dr. Cooperberg is a candidate member of the American Urological Association (AUA), Western Section of the AUA and the American College of Surgeons. He has written over 50 peer-reviewed scientific articles, nine chapters and has lectured nationally and internationally about malignant and benign urologic disease, with a particular focus on prostate cancer.
Dr. Cooperberg will speak on Molecular Risk Stratification.
See the full program outline here. http://wsaua.org/maui14/program